PVR and neoplasm: CD96 acts as a receptor for CD155, which activates CD96 and inhibits immune cell function in the tumor microenvironment.[7, 9, 12] Thus, determining the relationship between CD155 and CD96 in BCSCs is important for understanding chemoresistance in these tumors.